HIV Treatment Bulletin - Vol. 5, No. 9/10, October/November 2004
Graham McKerrow, HIV i-Base

Researchers from four countries have written to the Lancet calling on the pharmaceutical industry, the US Food and Drug Administration (FDA), researchers and the patient community to work together to assess the use of more than one new drug simultaneously to provide more effective so-called salvage therapy.

This growing patient group encompasses those at greatest risk of clinical disease but the pathophysiology of HIV and the available clinical data suggest that the successful outcome of future therapy will be determined by the number of new drugs used as well as the retained susceptibility to previous agents, argue the researchers from Britain, USA, France and Canada.

“Assessment of the use of more than one new drug simultaneously in the subsets of patients who are at greatest risk of clinical disease would, therefore, seem logical,” they write. “For instance, within the TORO (T-20 vs Optimised Regimen Only) studies there was a direct correlation between the success of virological suppression and immunological benefit with the number of active agents within the optimised background therapy used to support enfuvirtide. Unfortunately, to date, planned codevelopment of investigational agents has not occurred, and patients continue to be offered serial monotherapy along with potentially weakening regimens.”

The authors speculate that pharmaceutical companies might be concerned about compromising the clarity of single agent development and a “perceived fear” that the FDA would consider this action inappropriate. However, they say it has been publicly stated that few barriers exist to combining experimental agents in prelicensing studies in such a patient population.

The letter is signed by Mike Youle of the Royal Free Hospital, London, Cal Cohen of the Community Research Initiative, Boston, Massachusetts, USA, Christine Katlama of the Hopital de la Pitie Salpetriere, Paris, France, Dan Kuritzkes of Harvard Medical School, Cambridge, Massachusetts, USA, and Sharon Walmsley of the Toronto General Hospital, Toronto, Canada.

Ref: Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals. Lancet. 2004 Sep 18;364(9439):1036-7.

041010
IB040510-09

©2004. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone / Firestone Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.